2022 annual financial data

XTL Biopharmaceuticals 2022 Financial results

Direct answer

Revenue was -459,000 USD.

Operating income was -880,000 USD and net income was -1,348,000 USD.
Operating cash flow was -901,000 USD.

Get free XTL Biopharmaceuticals email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
-459,000 USD
Operating income
-880,000 USD
Net income
-1,348,000 USD
Operating cash flow
-901,000 USD